EMD.AX ASX
Emyria Limited
1W: -10.0%
1M: +0.0%
3M: +9.8%
YTD: -18.2%
1Y: +0.0%
3Y: -41.8%
5Y: -78.8%
A$0.04 ($0.03)
+0.00 (+0.00%)
Weekly Expected Move ±10.2%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market CapA$25.8M ($17.9M)
52W Range0.036-0.078
Volume658,264
Avg Volume1,437,859
Beta0.03
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOGregory Hutchinson
Employees6
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO Date2020-02-11
Websiteemyria.com
Level 1, 516 Hay Street
Subiaco, WA 6008
AU
Subiaco, WA 6008
AU
61 8 6559 2800
About Emyria Limited
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Latest News
No recent news
Recent Insider Trades
No insider trades found